Insight Molecular Diagnostics Inc 8-K/A, filed Jun 1, 2021

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K/A-1

CURRENTREPORT

Pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 19, 2021

OncoCyteCorporation

(Exact name of registrant as specified in its charter)

15Cushing

Irvine,California 92618

(Address of principal executive offices)

(949)409-7600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Forward-LookingStatements

Anystatements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,”“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially fromthe results anticipated in these forward-looking statements are contained in OncoCyte Corporation’s Annual Report on Form 10-Kand Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) under the heading “RiskFactors” and in other filings that Oncocyte may make with the SEC. Undue reliance should not be placed on these forward-lookingstatements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Exceptas required by law, Oncocyte disclaims any intent or obligation to update these forward-looking statements.

Referencesto “Oncocyte,” “we,” “us,” and “our” are references to OncoCyte Corporation.

Item9.01 - Financial Statements and Exhibits.

OncoCyte is filing this amendment to its Current Report on Form 8-K, originally filed with the Securities and Exchange Commission on April 19, 2021 (the “Original 8-K”), to disclose that Oncocyte has determined that financial statements of Chronix Biomedical, Inc. (“Chronix”) and pro forma financial information related to Oncocyte’s acquisition of Chronix are not required by Item 9.01 and, accordingly, will not be filed by amendment as exhibits to the Original 8-K.

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No.1 to Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

| 3 |

| --- |